Atorvastatin/CoenzymeQ10 in Congestive Heart Failure
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Change in cardiac Ejection Fraction (EF)
研究概览
简要总结
The aim of this study is to compare the effect of addition of combination of Atorvastatin/CoenzymeQ10 to standard congestive heart failure (CHF) treatment versus addition of Atorvastatin alone on CHF outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Care Provider)
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Documented Congestive hear failure
- •Ejection Fraction less than 40 percent
- •Compensated heart failure without hospital admission during previous three months
- •No change in type and dose of medications in the last months
- •New York Heart Association Function Class 2 to 4
排除标准
- •Acute coronary syndrome developing in the last month
- •Active myocarditis
- •Active pericarditis
- •Uncontrolled hypertension
- •Hepatic failure(Child B,C)
- •Pulmonary failure
- •Renal failure
- •Heart failure with KILLIP classification 3 and 4
研究组 & 干预措施
Coenzyme Q10 & Atorvastatin
10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
干预措施: Atorvastatin (Drug)
Coenzyme Q10 & Atorvastatin
10 mg Atorvastatin daily plus 100 mg Coenzyme Q10 pearl supplement twice daily for four months.
干预措施: Coenzyme Q10 (Drug)
Atorvastatin & placebo
10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
干预措施: Atorvastatin (Drug)
Atorvastatin & placebo
10 mg Atorvastatin daily and the placebo of Coenzyme Q10 pearl for four months.
干预措施: placebo for coenzyme Q10 (Drug)
结局指标
主要结局
Change in cardiac Ejection Fraction (EF)
时间窗: Baseline for the first time and after 4 months for the second time
For the determination of change in EF,cardiac EF was determined two times . Baseline :at the beginning of study(before intervention) and the second time after 4 months(after intervention).
次要结局
- Change in New York Heart Association Function Class(Baseline for the first time and after 4 months for the second time)
研究者
Amin Nemati
member of Isfahan Medical Students Research Committee
Isfahan University of Medical Sciences